Bullous Sweet's Syndrome and Pseudolymphoma Precipitated by IL-2 Therapy

Cutis

Volumn 85, Issue 4, 2010, Pages 206-213

  Rondina, Angela ^a   Watson, Alice C ^b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC FACTOR; INTERLEUKIN 2;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PATHOLOGY; PSEUDOLYMPHOMA;

DRUG ERUPTIONS; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-2; MALE; MIDDLE AGED; PSEUDOLYMPHOMA; SWEET SYNDROME;

EID: 77953147999     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Arduino RC, Nannini EC, Rodriguez-Barradas M, et al. Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) Vanguard Group; ESPRIT Executive Committee. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies. Clin Infect Dis. 2004; 39: 115-122.
2. Levy Y, Durier C, Krzysiek R, et al. ANRS 079 Study Group. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS. 2003; 17: 343-351.
3. Smith KA. Interleukin-2. Curr Opin Immunol. 1992; 4: 271-276.
4. Fossat C, Sainty D, Stoppa AM, et al. In vitro inhibition of interleukin-2-induced defective polymorphonuclear chemotaxis by TNF inhibitor. Eur J Haematol. 1993; 51: 13-17.
5. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Saf. 1992; 7: 417-433.
6. Wolkenstein P, Chosidow O, Wechsler J, et al. Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma. J Am Acad Dermatol. 1993; 28: 66-70.
7. Gaspari AA, Lotze MT, Rosenberg SA, et al. Dermatologic changes associated with interleukin 2 administration. JAMA. 1987; 258: 1624-1629.
8. Shulman KL, Thompson JA, Benyunes MC, et al. Adverse reactions to intravenous contrast media in patients treated with interleukin-2. J Immunother Emphasis Tumor Immunol. 1993; 13: 208-212.
9. Lee RE, Gaspari AA, Lotze MT, et al. Interleukin 2 and psoriasis. Arch Dermatol. 1988; 124: 1811-1815.
10. Ramseur WL, Richards F 2nd, Duggan DB. A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy. Cancer. 1989; 63: 2005-2007.
11. Prussick R, Plott RT, Stanley JR. Recurrence of pemphigus vulgaris associated with interleukin 2 therapy. Arch Dermatol. 1994;130:890-893.
12. Tranvan A, Pezen DS, Medenica M, et al. Interleukin-2 associated linear IgA bullous dermatosis. J Am Acad Dermatol. 1996; 35(5, pt 2): 865-867.
13. Guillaume JC, Escudier B, Espange E, et al. Bullous dermatosis with linear IgA deposits along the basement membrane during treatment with gamma interferon and interleukin-2 [in French]. Ann Dermatol Venereol. 1990; 117: 899-902.
14. Staunton MR, Scully MC, Le Boit PE, et al. Lifethreatening bullous skin eruptions during interleukin-2 therapy. J Natl Cancer Inst. 1991; 83: 56-57.
15. Hofmann M, Audring H, Sterry W, et al. Interleukin-2-associated bullous drug dermatosis. Dermatology. 2005; 210: 74-75.
16. Wiener JS, Tucker JA Jr, Walther PJ. Interleukin-2-induced dermatotoxicity resembling toxic epidermal necrolysis. South Med J. 1992; 85: 656-659.
17. O'Reilly F, Feldman E, Yang J, et al. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2. J Am Acad Dermatol. 2003; 48: 602-604.
18. Brun Romero FM, Terrón Pernía JA. Blister reaction after the administration of interleukin-2 [in Spanish]. Med Clin (Barc). 2004; 123: 637.
19. Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol. 1995; 33: 393-410.
20. Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964; 76: 349-356.
21. Von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994; 31: 535-556.
22. Thibault MJ, Billick RC, Srolovitz H. Minocyclineinduced Sweet's syndrome. J Am Acad Dermatol. 1992; 27(5, pt 2): 801-804.
23. Tefany FJ, Georgouras K. A neutrophilic reaction of Sweet's syndrome type associated with the oral contraceptive. Australas J Dermatol. 1991; 32: 55-59.
24. Arbetter KR, Hubbard KW, Markovic SN, et al. Case of granulocyte colony-stimulating factor-induced Sweet's syndrome. Am J Hematol. 1999; 61: 126-129.
25. Al-Saad K, Khanani MF, Naqvi A, et al. Sweet syndrome developing during treatment with all-trans retinoic acid in a child with acute myelogenous leukemia. J Pediatr Hematol Oncol. 2004; 26: 197-199.
26. Gilmour E, Chalmers RJ, Rowlands DJ. Drug-induced Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with hydralazine. Br J Dermatol. 1995; 133: 490-491.
27. Retief CR, Malkinson FD. Nitrofurantoin-associated Sweet's syndrome. Cutis. 1999; 63: 177-179.
28. Del Giudice P, Vandenbos F, Perrin C, et al. Sweet's syndrome following abacavir therapy. J Am Acad Dermatol. 2004; 51: 474-475.
29. Fye KH, Crowley E, Berger TG, et al. Celecoxib-induced Sweet's syndrome. J Am Acad Dermatol. 2001; 45: 300-302.
30. Govindarajan G, Bashir Q, Kuppuswamy S, et al. Sweet syndrome associated with furosemide. South Med J. 2005; 98: 570-572.
31. Ayirookuzhi SJ, Ma L, Ramshesh P, et al. Imatinibinduced Sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol. 2005; 141: 368-370.
32. Guimerá FJ, Garcia-Bustinduy M, Noda A, et al. Diazepam-associated Sweet's syndrome. Int J Dermatol. 2000; 39: 795-798.
33. Clark BM, Homeyer DC, Glass KR, et al. Clindamycin-induced Sweet's syndrome. Pharmacotherapy. 2007; 27: 1343-1346.
34. Hilliquin P, Marre JP, Cormier C, et al. Sweet's syndrome and monoarthritis in a human immunodeficiency virus- positive patient. Arthritis Rheum. 1992;35:484-486.
35. Bevilacqua S, Hermans P, Van Laethem Y, et al. Sweet's syndrome in an HIV-infected patient. AIDS. 1999;13: 728-729.
36. Brady RC, Morris J, Connelly BL, et al. Sweet's syndrome as an initial manifestation of pediatric human immunodeficiency virus infection. Pediatrics. 1999; 104 (5, pt 1): 1142-1144.
37. Giasuddin AS, El-Orfi AH, Ziu MM, et al. Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol. 1998; 39: 940-943.
38. Klempner MS, Noring R, Mier JW, et al. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med. 1990; 322: 959-965.
39. Klapholz L, Ackerstein A, Goldenhersh MA, et al. Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT. Bone Marrow Transplant. 1993; 11: 443-446.
40. Baars JW, Coenen JL, Wagstaff J, et al. Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2. Br J Cancer. 1992; 66: 698-699.